Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of generic empagliflozin + linagliptin 25/5 mg vs Glyxambi 25/5 mg in healthy Thai volunteers (fasting)
TCTR20251016005Phase 1Active, not recruiting
- Sponsor
- International Bio Service
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of empagliflozin + linagliptin, empagliflozin and linagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by International Bio Service. Started Dec 2025; status: active, not recruiting.
02
Drugs
empagliflozin + linagliptinempagliflozinlinagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on TCTR20251016005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20251016005.